gamma-aminobutyric acid has been researched along with Apnea in 15 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Apnea: A transient absence of spontaneous respiration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report two cases of infants with NI, identified to have significant improvement in apnea following empiric treatment with gabapentin for presumed central pain and/or visceral hyperalgesia." | 7.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| " This secondary hypertonia may contribute to apnea as a result of alterations in airway tone and chest wall movement." | 7.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| "Infants with NI and apnea should have careful pain assessment and treatment, when considering other causes and interventions for apnea." | 7.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| "We tested the hypotheses that elevated body temperature would prolong reflex apnea following electrical stimulation of the superior laryngeal nerve (SLN) in decerebrate neonatal piglets and that thermal prolongation of reflex apnea after stimulation of the SLN depended on GABAergic mechanisms." | 7.74 | GABAergic processes mediate thermal prolongation of the laryngeal reflex apnea in decerebrate piglets. ( Bartlett, D; Böhm, I; Leiter, JC; Xia, L, 2007) |
| "Activation of the laryngeal mucosa results in apnea that is mediated through, and can be elicited via electrical stimulation of, the superior laryngeal nerve (SLN)." | 7.74 | Activation of central adenosine A(2A) receptors enhances superior laryngeal nerve stimulation-induced apnea in piglets via a GABAergic pathway. ( Abu-Shaweesh, JM, 2007) |
| "Stimulation of the superior laryngeal nerve (SLN) results in apnea in animals of different species, the mechanism of which is not known." | 7.71 | Central GABAergic mechanisms are involved in apnea induced by SLN stimulation in piglets. ( Abu-Shaweesh, JM; Dreshaj, IA; Haxhiu, MA; Martin, RJ, 2001) |
| "We report two cases of infants with NI, identified to have significant improvement in apnea following empiric treatment with gabapentin for presumed central pain and/or visceral hyperalgesia." | 3.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| " This secondary hypertonia may contribute to apnea as a result of alterations in airway tone and chest wall movement." | 3.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| "Infants with NI and apnea should have careful pain assessment and treatment, when considering other causes and interventions for apnea." | 3.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| " A major debilitating phenotype in affected females is frequent apneas, and heterozygous Mecp2-deficient female mice mimic the human respiratory disorder." | 3.76 | Correction of respiratory disorders in a mouse model of Rett syndrome. ( Abdala, AP; Bissonnette, JM; Dutschmann, M; Paton, JF, 2010) |
| "We tested the hypotheses that elevated body temperature would prolong reflex apnea following electrical stimulation of the superior laryngeal nerve (SLN) in decerebrate neonatal piglets and that thermal prolongation of reflex apnea after stimulation of the SLN depended on GABAergic mechanisms." | 3.74 | GABAergic processes mediate thermal prolongation of the laryngeal reflex apnea in decerebrate piglets. ( Bartlett, D; Böhm, I; Leiter, JC; Xia, L, 2007) |
| "Activation of the laryngeal mucosa results in apnea that is mediated through, and can be elicited via electrical stimulation of, the superior laryngeal nerve (SLN)." | 3.74 | Activation of central adenosine A(2A) receptors enhances superior laryngeal nerve stimulation-induced apnea in piglets via a GABAergic pathway. ( Abu-Shaweesh, JM, 2007) |
| " Microinjection of the bicuculline produced apnea, whereas microinjection of CGP-35348 produced a decrease in Ti and an increase in expiratory duration." | 3.71 | GABA-mediated neurotransmission in the ventrolateral NTS plays a role in respiratory regulation in the rat. ( Ferreira, M; Gillis, RA; Hernandez, YM; Sahibzada, N; Wasserman, AM, 2002) |
| "Stimulation of the superior laryngeal nerve (SLN) results in apnea in animals of different species, the mechanism of which is not known." | 3.71 | Central GABAergic mechanisms are involved in apnea induced by SLN stimulation in piglets. ( Abu-Shaweesh, JM; Dreshaj, IA; Haxhiu, MA; Martin, RJ, 2001) |
| " The dose-response relationship and specifity of this effect were investigated." | 1.26 | Transient apnoea after systemic injection of GABA in the rat. ( Hagmüller, K; Holzer, P, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Revol, B | 1 |
| Jullian-Desayes, I | 1 |
| Bailly, S | 1 |
| Mallaret, M | 1 |
| Tamisier, R | 1 |
| Agier, MS | 1 |
| Lador, F | 1 |
| Joyeux-Faure, M | 1 |
| Pépin, JL | 1 |
| Matagne, V | 1 |
| Ehinger, Y | 1 |
| Saidi, L | 1 |
| Borges-Correia, A | 1 |
| Barkats, M | 1 |
| Bartoli, M | 1 |
| Villard, L | 1 |
| Roux, JC | 1 |
| Abdala, AP | 1 |
| Dutschmann, M | 1 |
| Bissonnette, JM | 1 |
| Paton, JF | 1 |
| Hauer, J | 1 |
| Mackey, D | 1 |
| Kaczyńska, K | 1 |
| Szereda-Przestaszewska, M | 1 |
| Wasserman, AM | 1 |
| Ferreira, M | 1 |
| Sahibzada, N | 1 |
| Hernandez, YM | 1 |
| Gillis, RA | 1 |
| Ikeda, K | 1 |
| Onimaru, H | 1 |
| Yamada, J | 1 |
| Inoue, K | 1 |
| Ueno, S | 1 |
| Onaka, T | 1 |
| Toyoda, H | 1 |
| Arata, A | 1 |
| Ishikawa, TO | 1 |
| Taketo, MM | 1 |
| Fukuda, A | 1 |
| Kawakami, K | 1 |
| Martin, RJ | 2 |
| Wilson, CG | 1 |
| Abu-Shaweesh, JM | 3 |
| Haxhiu, MA | 2 |
| Böhm, I | 1 |
| Xia, L | 1 |
| Leiter, JC | 1 |
| Bartlett, D | 1 |
| Johnston, BM | 1 |
| Gluckman, PD | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Tarakanov, IA | 1 |
| Safonov, VA | 1 |
| Monin, P | 1 |
| Dreshaj, IA | 1 |
| Holzer, P | 1 |
| Hagmüller, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms[NCT02790034] | Phase 2/Phase 3 | 129 participants (Actual) | Interventional | 2016-10-26 | Terminated (stopped due to The study did not demonstrate evidence of efficacy on the primary or secondary efficacy variables) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Caregiver-rated Impression of Change (CIC): 7-point scale requiring the caregiver to rate how much the patient's illness has improved or worsened relative to the baseline state.~7-point Likert-type scale for which ratings range from 1 = very much improved to 7 = very much worse, with 4 = no change. This caregiver-rated measure considered activities, behavior, mood and functioning. This rating was performed in consultation with the study Investigator but was based largely on the caregivers' evaluation during the reporting period. The single rating of the CIC was to be based on changes in the following domains: • Activities (watching TV, interest in conversations around her, cooperation during toileting, dressing/bathing, etc.), • Communication (verbal or by eye movements, hand movements, or head movements), • Behavior (agitation, refusal to feed, scratching, social avoidance), • Participation in family/outdoor/social events)" (NCT02790034)
Timeframe: 24 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Sarizotan Low Dose | 3.6 |
| Sarizotan High Dose | 3.5 |
| Placebo | 3.4 |
Measured as the percent change in the number of apnea episodes per hour during awake time, calculated using an ambulatory data acquisition system (BioRadioTM) as part of home monitoring procedure. BioRadioTM record specific respiratory and cardiac parameters. (NCT02790034)
Timeframe: Baseline up to week 24
| Intervention | % of change in mean counts per hr (Least Squares Mean) |
|---|---|
| Sarizotan Low Dose | 1.54 |
| Sarizotan High Dose | 13.211 |
| Placebo | 18.503 |
2 reviews available for gamma-aminobutyric acid and Apnea
| Article | Year |
|---|---|
Role of inhibitory neurotransmitter interactions in the pathogenesis of neonatal apnea: implications for management.
Topics: Animals; Animals, Newborn; Apnea; Bicuculline; Female; gamma-Aminobutyric Acid; Humans; Infant, Newb | 2004 |
Pharmacology of respiratory control in neonates and children.
Topics: Adenosine; Animals; Apnea; Chemoreceptor Cells; Child; Child, Preschool; Endorphins; gamma-Aminobuty | 1997 |
13 other studies available for gamma-aminobutyric acid and Apnea
| Article | Year |
|---|---|
Baclofen and sleep apnoea syndrome: analysis of VigiBase, the WHO pharmacovigilance database.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Alcoholism; Apnea; Baclofen; Database | 2018 |
A codon-optimized Mecp2 transgene corrects breathing deficits and improves survival in a mouse model of Rett syndrome.
Topics: Amines; Animals; Apnea; Codon; Cyclohexanecarboxylic Acids; Dependovirus; Disease Models, Animal; Di | 2017 |
Correction of respiratory disorders in a mouse model of Rett syndrome.
Topics: Animals; Apnea; Disease Models, Animal; Female; GABA Antagonists; gamma-Aminobutyric Acid; Male; Met | 2010 |
Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment.
Topics: Amines; Analgesics; Apnea; Central Nervous System; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2013 |
Apnoeic response to stimulation of peripheral GABA receptors in rats.
Topics: Animals; Apnea; Bicuculline; Carotid Sinus; GABA Antagonists; gamma-Aminobutyric Acid; Male; Picroto | 2002 |
GABA-mediated neurotransmission in the ventrolateral NTS plays a role in respiratory regulation in the rat.
Topics: Animals; Apnea; Baclofen; Bicuculline; Cardiovascular System; Fluorescent Antibody Technique; GABA A | 2002 |
Malfunction of respiratory-related neuronal activity in Na+, K+-ATPase alpha2 subunit-deficient mice is attributable to abnormal Cl- homeostasis in brainstem neurons.
Topics: Amino Acid Sequence; Animals; Apnea; Chlorides; Electric Stimulation; Facial Nerve; Fetus; gamma-Ami | 2004 |
GABAergic processes mediate thermal prolongation of the laryngeal reflex apnea in decerebrate piglets.
Topics: Analysis of Variance; Animals; Apnea; Body Temperature; Chemoreceptor Cells; Decerebrate State; Elec | 2007 |
Activation of central adenosine A(2A) receptors enhances superior laryngeal nerve stimulation-induced apnea in piglets via a GABAergic pathway.
Topics: Adenosine; Animals; Animals, Newborn; Apnea; Bicuculline; Blood Pressure; Cisterna Magna; Disease Mo | 2007 |
GABA-mediated inhibition of breathing in the late gestation sheep fetus.
Topics: Animals; Apnea; Female; Fetal Hypoxia; Fetus; gamma-Aminobutyric Acid; Gestational Age; Muscimol; Ox | 1983 |
[The participation of the GABAergic system of the brain in shaping the breathing rhythm].
Topics: Animals; Apnea; Baclofen; Cats; Electromyography; Female; gamma-Aminobutyric Acid; Male; Medulla Obl | 1993 |
Central GABAergic mechanisms are involved in apnea induced by SLN stimulation in piglets.
Topics: Animals; Animals, Newborn; Apnea; Bicuculline; Brain Stem; Cisterna Magna; Electric Stimulation; Ele | 2001 |
Transient apnoea after systemic injection of GABA in the rat.
Topics: Animals; Apnea; Crotonates; Depression, Chemical; Dose-Response Relationship, Drug; Drug Interaction | 1979 |